These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33463117)

  • 1. Evaluating the Immune Response of Recombinant H1N1 Hemagglutinin with MF59 Adjuvant in Animal Model as a Novel Alternative to the Influenza Vaccine.
    Rashedi N; Taghizadeh M; Mohamadynejad P; Mahdavi M; Jalalirad R
    Iran J Allergy Asthma Immunol; 2020 Oct; 19(5):497-508. PubMed ID: 33463117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice.
    Ou H; Yao H; Yao W; Wu N; Wu X; Han C; Cheng L; Chen K; Chen H; Li L
    Vaccine; 2016 Apr; 34(20):2362-70. PubMed ID: 27013436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
    Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
    Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
    Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development.
    Chen TH; Liu WC; Chen IC; Liu CC; Huang MH; Jan JT; Wu SC
    Vaccine; 2019 Nov; 37(47):6933-6941. PubMed ID: 31383491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice.
    Wu XX; Deng XL; Yu DS; Yao W; Ou HL; Weng TH; Hu CY; Hu FY; Wu NP; Yao H; Zhang FC; Li LJ
    Cell Physiol Biochem; 2018; 46(2):633-643. PubMed ID: 29617693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
    Hauser MI; Muscatello DJ; Soh ACY; Dwyer DE; Turner RM
    Vaccine; 2019 Jul; 37(31):4246-4255. PubMed ID: 31253447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
    van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets.
    Han HJ; Song MS; Park SJ; Byun HY; Robles NJC; Ha SH; Choi YK
    J Microbiol; 2019 Feb; 57(2):163-169. PubMed ID: 30706345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation of Recombinant H1N1 Hemagglutinin in MF59 and Alum Adjuvants: A Comparison of the Vaccines Potency and Efficacy in BALB/C Mice.
    Sepasi A; Ghafourian M; Taghizadeh M; Mahdavi M
    Viral Immunol; 2023; 36(6):401-408. PubMed ID: 37504965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine.
    Sun Y; Bian C; Xu K; Hu W; Wang T; Cui J; Wu H; Ling Z; Ji Y; Lin G; Tian L; Zhou Y; Li B; Hu G; Yu N; An W; Pan R; Zhou P; Leng Q; Huang Z; Ma X; Sun B
    PLoS One; 2010 Dec; 5(12):e14270. PubMed ID: 21151563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).
    Baudner BC; Ronconi V; Casini D; Tortoli M; Kazzaz J; Singh M; Hawkins LD; Wack A; O'Hagan DT
    Pharm Res; 2009 Jun; 26(6):1477-85. PubMed ID: 19255727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immune protective effectiveness of seasonal influenza spilt vaccine against homologous and heterogonous subtypes of influenza virus in mice].
    Huang BY; Wang XP; Wang WL; Hu W; Gao Q; Tan WJ; Ruan L
    Bing Du Xue Bao; 2011 May; 27(3):265-73. PubMed ID: 21774253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization.
    Stark FC; Akache B; Ponce A; Dudani R; Deschatelets L; Jia Y; Sauvageau J; Williams D; Jamshidi MP; Agbayani G; Wachholz K; Harrison BA; Li X; Krishnan L; Chen W; McCluskie MJ
    Vaccine; 2019 Nov; 37(47):7108-7116. PubMed ID: 31383490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.